Tiancheng (Germany) Pharmaceutcial Holdings AG, a holding company indirectly controlled by Creat Group Co., Ltd., has informed Biotest AG company that it intends to conclude a domination and profit and loss transfer agreement (Beherrschungs- und Gewinnabfürhungsvertrag) between Biotest AG as the controlled and profit-transferring company and to approve the conclusion of such a corporate agreement at a general meeting of Biotest AG.
Biotest AG assumes that the compensation and settlement arrangements for the outside shareholders of Biotest AG will be determined in accordance with the legal requirements and on the basis of a company valuation. The intended domination and profit and loss transfer agreement requires the approval of the Annual General Meeting of Biotest AG in order to be effective.
On May 18, 2017, Tiancheng published the offer document for its voluntary public takeover offer to the shareholders of Biotest AG for the acquisition of all no-par value ordinary shares (ISIN DE0005227201) and all no-par value preferred shares (ISIN DE0005227235) of Biotest AG. The acceptance period for the Takeover Offer expired on 15 June 2017, and the additional acceptance period pursuant to § 16 (2) sentence 1 WpÜG ended on 4 July 2017. The purchase agreements for the Biotest shares submitted during the Acceptance Period and the Additional Acceptance Period were completed on January 31, 2018.
Biotest AG assumes that the compensation and settlement arrangements for the outside shareholders of Biotest AG will be determined in accordance with the legal requirements and on the basis of a company valuation. The intended domination and profit and loss transfer agreement requires the approval of the Annual General Meeting of Biotest AG in order to be effective.
On May 18, 2017, Tiancheng published the offer document for its voluntary public takeover offer to the shareholders of Biotest AG for the acquisition of all no-par value ordinary shares (ISIN DE0005227201) and all no-par value preferred shares (ISIN DE0005227235) of Biotest AG. The acceptance period for the Takeover Offer expired on 15 June 2017, and the additional acceptance period pursuant to § 16 (2) sentence 1 WpÜG ended on 4 July 2017. The purchase agreements for the Biotest shares submitted during the Acceptance Period and the Additional Acceptance Period were completed on January 31, 2018.
No comments:
Post a Comment